|
| Monday, 6 July 2020, 11:15 HKT/SGT | |
| |
|
|
|
HONG KONG, July 6, 2020 - (ACN Newswire) - Thanks to capital market's growing expectation for the aging population and accelerated substitution of imported medical devices, China's medical devices industry has entered a golden age of rapid development. Hong Kong-listed medical devices company, MicroPort Scientific Corporation ("MicroPort",stock code: 00853) - which has positioned in ten business segments including cardiovascular devices, orthopedics devices, and cardiac rhythm management business - was favored by the capital market in 2020 and obtained substantial attention from a lot of heavyweight strategic investors.
Following its announcement on July 2 in relation to completion of the placing of 65,958,000 new shares and raising over HK$1.5 billion at a price with the lowest discount among all primary placings of healthcare companies listed in Hong Kong in the last 5 years, MicroPort announced on 5 July that its subsidiary - MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which focuses on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders - has entered into definitive agreements in connection with its Series B financing with total investment proceeds US$105 million. With the investments, MicroPort CRM's post-money valuation reaches about US$400 million. Hillhouse Capital Group will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor, Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly owned subsidiary. These investments fully demonstrated investors' confidence on the development of medical devices industry and MicroPort CRM business.
Originally acquired in April 2018, MicroPort CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. Headquartered in Clamart (outside Paris) France, MicroPort CRM has dedicated R&D teams in Clamart (outside Paris) and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort CRM employs approximately 950 employees globally.
For decades, MicroPort CRM has been at the forefront of innovation in the CRM industry and has implanted more than one million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort CRM launched the PLATINIUMTM family of implantable defibrillators, which has the longest service life of any implantable defibrillator on the market, reducing the risks associated to frequent replacements. In 2019, the company launched ENOTM, TEOTM and OTOTM, the world's smallest family of pacemakers, 1.5T and 3T MRI conditional. In the CRT field, the company innovated with the SonRTM sensor, the world's only contractility sensor for automatic optimization of cardiac resynchronization, which, in a landmark trial called RESPOND-CRT, revealed that SonRTM is associated with a 35% reduction in the risk of hospitalization for heart failure. MicroPort CRM continues to innovate in CRT by developing AXONETM, an ultra-thin 1.2 F (0.4 mm) left ventricular lead, which will enable MicroPort CRM to lead the industry in expanding CRT therapy options.
MicroPort CRM will soon launch a new family of pacemakers, ALIZEATM and BOREATM, featuring Bluetooth technology and wireless remote monitoring, and plans to launch a complete new line of defibrillator systems in 2021, including devices and leads, 1.5T and 3T MRI conditional. The market introduction of these products will provide an additional inflection point for the growth prospects of the CRM franchise.
Topic: Press release summary
Sectors: Daily Finance, Daily News, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Thursday, July 16, 2026 9:00:00 PM
|
|
|
Community Creates Mega Artwork for HKTDC 60th Anniversary
July 16, 2026 19:15 HKT/SGT
|
|
|
Cornerstone Robotics to Present at the 2nd Global Health Summit (GHS 2026) 
July 16, 2026 14:07 HKT/SGT
|
|
|
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Wednesday, July 15, 2026 11:18:00 PM
|
|
|
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Wednesday, July 15, 2026 10:51:00 PM
|
|
|
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Wednesday, July 15, 2026 10:21:00 PM
|
|
|
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
Wednesday, July 15, 2026 9:53:00 PM
|
|
|
Hitachi Rail achieves EcoVadis platinum medal, ranking among the top 1% of companies worldwide for sustainability performance
Wednesday, July 15, 2026 9:35:00 PM
|
|
|
AI Labs Launches AI-Powered Investment Intelligence Platform to Bring Advanced Technology Stock Analytics to Retail Investors
July 15, 2026 21:20 HKT/SGT
|
|
|
Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks all open today
July 15, 2026 19:39 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
